Emma studied biochemistry at Imperial College London then stayed on for a Masters and PhD on her favourite topic, immunology. After almost a decade there, she braved the move out of London (a whole 12 miles south) and joined The Institute of Cancer Research to study multiple myeloma, a white blood cell cancer. She left the lab for the final time in 2010 and, after a couple of years at Breakthrough Breast Cancer, joined the Science Communications team at Cancer Research UK.
Our research has led to new clinical trials testing a combination of hormone therapies in women with early, double-positive breast cancer.
A researcher explains an early stage clinical trial testing the potential of a new type of immunotherapy to treat neuroblastoma.
Our researchers in Glasgow might have found a way to shut down certain cancer cells’ fuel supply with a specially designed diet.
We’re backing a new project that could boost our understanding of pancreatic cancer and increase opportunities for patients to join clinical trials.
In part 3 of our World Cancer Day series, we take a look at how liver cancer affects different regions across the world.
For this year’s World Cancer Day we’re looking at how the rates of 4 types of cancer vary around the world, and why.
Why is the shape of a cancer cell so important for predicting how the disease will behave? Our scientists may have an answer.
We take a look at some of our new, pioneering clinical trials.